Netflix Stock Price Soars After Earnings Report Record New Memberships
Netflix stock price ( NASDAQ: NFLX ) is up more than 13% in the after-hours following its release of the fourth-quarter earnings report for fiscal year 2024. The streaming company recorded a 16% increase in revenue year-over-year, reaching 19% on a foreign exchange (F/X) neutral basis, which the
If you invested $1000 in Chipotle Mexican Grill (NYSE:CMG) 5 years ago, here's how much it's worth today
They say, “If it looks like a restaurant, cooks food like a restaurant, and serves food like a restaurant, then it’s probably a restaurant.”. However, this might not be how investors see Chipotle Mexican Grill ( NYSE:CMG ). Chipotle’s stock is currently trading at a P/E ratio of around 54, while many
Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET
GlobeNewswire Inc.
23 minutes ago
WALTHAM, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it
Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease
GlobeNewswire Inc.
3 hours ago
CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the publication of Phase 1/2
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting
GlobeNewswire Inc.
3 hours ago
- Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92% of patients with untreated indolent non-Hodgkin lymphoma (iNHL) comparing favorably to an approximate 50% historical CR rate for R2 alone - Dat
CellCentric Presents Positive Phase 2 Dose Optimization Data for Inobrodib in Multiple Myeloma at ASH Annual Meeting
Newsfile
3 hours ago
- Inobrodib in combination with pomalidomide + dexamethasone (InoPd) demonstrates strong clinical efficacy and a tolerable safety profile in heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients -- Observed response rates of 60-75%
Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting
GlobeNewswire Inc.
4 hours ago
Poster outlines clinical benefit with acceptable safety profile across 9 tested dosing regimensAccelerated step-up dosing and higher dosing frequency is feasible and results in increased exposure Six of eight responders presented with low bone marrow
EnglishSparklingWines.com Releases Updated Analysis: Highlights Growing Attention Toward English Sparkling Wine
Newsfile
4 hours ago
London, United Kingdom--(Newsfile Corp. - December 7, 2025) - UK-based e-commerce platform dedicated to Britain's greatest fizz, EnglishSparklingWines.com, has presented an updated analysis on the category's increasing global reputation. The newly re
Payre: Solving Late Payments Woes by Making Legal Debt Recovery Platform Accessible to All
Newsfile
4 hours ago
New York, New York--(Newsfile Corp. - December 7, 2025) - For the first time, creditors can recover debtor arrears through an accountant or lawyer with zero upfront costs -and it's 10x faster.To view an enhanced version of this graphic, please visit:
Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
GlobeNewswire Inc.
Yesterday at 10:30 PM GMT
― Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at the Week 6 timepoint (n=12): mean absolute HbF in the 20 mg cohort increased by 9.9% at Week 6 (vs. 5.6% at Week 6 in the 12 mg cohort); 7 of
TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
GlobeNewswire Inc.
Yesterday at 10:30 PM GMT
Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23) and overall survival (HR=0.61; p=0.52) 3/3 (100%) of TSC-101-treated patients who reached two-year follow-up remained relapse-free vs. 1/4 (25%) in the control a
Raythink Ranks 9th in 2025 a&s Security 50, Showcasing AI-Driven Thermal Imaging & Security Solutions
Newsfile
Yesterday at 7:17 PM GMT
Yantai, China--(Newsfile Corp. - December 6, 2025) - a&s magazine, a globally recognized media platform focused on the security industry, recently announced the 2025 Security 50 list, with Raythink Technology proudly ranking 9th among the top 50 comp
